![]() |
Volumn 52, Issue 1, 2001, Pages 1-7
|
Learning from previous responses in phase I dose-escalation studies
a
|
Author keywords
Clinical trials; Continual reassessment method; Dose finding; First in man
|
Indexed keywords
ANTINEOPLASTIC AGENT;
QUERCETIN;
CANCER CHEMOTHERAPY;
CLINICAL PHARMACOLOGY;
CLINICAL TRIAL;
DECISION MAKING;
DOSE CALCULATION;
DOSE RESPONSE;
DRUG SAFETY;
HUMAN;
MAXIMUM TOLERATED DOSE;
NEPHROTOXICITY;
ONCOLOGY;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
PRODUCTIVITY;
REVIEW;
RISK ASSESSMENT;
STATISTICAL ANALYSIS;
|
EID: 0034832384
PISSN: 03065251
EISSN: None
Source Type: Journal
DOI: 10.1046/j.0306-5251.2001.01383.x Document Type: Review |
Times cited : (18)
|
References (24)
|